Home Press Releases Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

by Press Room


 


(EMAILWIRE.COM, October 13, 2023 ) The report “Viral Vector Manufacturing Market by Type (Viral Vector [Retroviruses, Adenoviruses, AAV, Lentiviruses], Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User & Region – Global Forecast to 2028″, The global viral vector & plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market is driven by rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene and cell therapies, leading to expanded applications and adoption of viral vector and plasmid DNA manufacturing technologies.

Download PDF Brochure :-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89341986

The Plasmid DNA segment accounted for the largest share, by type in the viral vector & plasmid DNA manufacturing market in 2022.

By type, the viral vector & plasmid DNA manufacturing market has been further categorized as viral vector and plasmid DNA. The plasmid DNA segment held the largest share of the global viral vector and plasmid DNA manufacturing market in 2022. This can be attributed to Increasing R&D and the growing launches of plasmid DNA production platforms. Plasmid DNA plays a crucial role in this research and developments. Plasmids are often used in genetic engineering and biotechnology for various purposes, including gene cloning, gene expression, and recombinant protein production.

The downstream manufacturing segment accounted for the largest share of the workflow segment in the viral vector and plasmid DNA manufacturing market in 2022.

Based on workflow, the global viral vector and plasmid DNA manufacturing market has been segmented into upstream manufacturing and downstream manufacturing. The downstream manufacturing segment held the largest market share in 2022. The large share of this segment can be attributed to development of efficient purification techniques and processes that result in high yields of purified products.

The North America region catered the largest share of the viral vector and plasmid DNA manufacturing market in 2022.

The viral vector and plasmid DNA manufacturing market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in viral vector and plasmid DNA manufacturing technologies, and collaborative initiatives contribute to the growth of the viral vector and plasmid DNA manufacturing market in the North America region. Additionally, North America faces a significant burden of chronic diseases, including cancer, cardiovascular diseases, and neurological disorders. The increasing prevalence of chronic diseases in the region drives the demand for viral vector and plasmid DNA manufacturing for both research and clinical applications.

Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=89341986

Key players in the viral vector and plasmid DNA manufacturing market include Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), Catalent Inc. (US), WuXi AppTec (China), FUJIFILM Corporation (Japan), GenScript Biotech Corporation (US), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Novartis AG (Switzerland), Precision Biosciences (US), Bluebird Bio, Inc. (US), Sartorius AG (Germany), Danaher Corporation (US), SIRON Biotech (Germany), VGXI, Inc. (US), Waisman Biomanufacturing (US), Kaneka Eurogentec S.A. (Belgium), PlasmidFactory GmbH (Germany), ATUM (US), Addgene (US), Cell and Gene Therapy Catapult (UK), Batavia biosciences (Netherlands), and Altogen Biosystems (US).



Source link

You may also like

About Us

Arab Africana™ publishes and aggregates business, socio-economic, Tech and industrial news on Arab countries in Africa.

 

We provide press release distribution to media in Africa including Arab countries, the Arab world and the GCC/MENA regions. To submit a press release for distribution, contact us today.

Trending Now

Newsletter

    ArabAfricana logo-white

    Arab Africana is part of GroupWeb Media Network. ©  2024 GroupWeb Media LLC